Cases
Tetraphase Pharmaceuticals, Inc. (TTPH)
Securities Class Action
Overview
Overview
- Date:
- 1/28/2019
- Company Name:
- Tetraphase Pharmaceuticals, Inc.
- Stock Symbol:
- TTPH
- Class Period:
- FROM 3/8/2017 TO 2/12/2018
- Status:
- Closed/Complete
NEW YORK, January 28, 2019 – Bragar Eagel & Squire, P.C. is investigating potential claims against certain officers and directors of Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH).
On July 27, 2018, a complaint was filed alleging that between March 8, 2017 and February 12, 2018, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, the complaint alleges that defendants failed to disclose: (1) Tetraphase was increasing the patient enrollment in its IGNITE3 trial from 1,000 patients to 1,200 patients to meet the trials primary endpoints (within the 10% non-inferiority margin); (2) the enrollment of more patients in the trial indicated that the existing population was inadequate to meet the trials primary endpoints; and (3) that, as a result of the foregoing, defendants statements about Tetraphase’s business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis.
If you are a long term stockholder of Tetraphase, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
On July 27, 2018, a complaint was filed alleging that between March 8, 2017 and February 12, 2018, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, the complaint alleges that defendants failed to disclose: (1) Tetraphase was increasing the patient enrollment in its IGNITE3 trial from 1,000 patients to 1,200 patients to meet the trials primary endpoints (within the 10% non-inferiority margin); (2) the enrollment of more patients in the trial indicated that the existing population was inadequate to meet the trials primary endpoints; and (3) that, as a result of the foregoing, defendants statements about Tetraphase’s business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis.
If you are a long term stockholder of Tetraphase, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.